# AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy

> **NCT00102323** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 63 (actual)

## Conditions studied

- Thrombocytopenia
- Idiopathic Thrombocytopenic Purpura

## Interventions

- **DRUG:** Placebo
- **BIOLOGICAL:** AMG 531

## Key facts

- **NCT ID:** NCT00102323
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03-29
- **Primary completion:** 2006-09-01
- **Final completion:** 2007-03-01
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2022-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102323, "AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00102323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*